8-K: Jazz Pharmaceuticals Receives FDA Accelerated Approval for Ziihera in HER2-Positive Biliary Tract Cancer

The FDA has granted accelerated approval to Jazz Pharmaceuticals' Ziihera for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

Summary

• Jazz Pharmaceuticals has received accelerated FDA approval for Ziihera (zanidatamab-hrii) for treating adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC).
• This approval is based on a 52% objective response rate and a median duration of response of 14.9 months observed in the HERIZON-BTC-01 clinical trial.
• Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.
• The approval is accelerated, and continued approval may depend on verification of clinical benefit in a confirmatory trial.
• A Phase 3 confirmatory trial, HERIZON-BTC-302, is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA approval of a new treatment option for a difficult-to-treat cancer, with promising efficacy data. However, the accelerated nature of the approval and the potential for serious adverse reactions temper the overall sentiment.

Positives

• Ziihera offers a new treatment option for patients with HER2-positive biliary tract cancer, a disease with limited treatment options.
• The 52% objective response rate and 14.9-month median duration of response are promising results for this patient population.
• Ziihera is the first and only dual HER2-targeted bispecific antibody approved for this indication, representing a significant advancement.
• The drug has received Breakthrough Therapy Designation and Fast Track designations from the FDA, highlighting its potential.
• The company is actively investigating zanidatamab in other tumor types, including gastroesophageal adenocarcinomas and metastatic breast cancer.

Negatives

• The approval is accelerated, and continued approval is contingent upon verification of clinical benefit in a confirmatory trial.
• Serious adverse reactions occurred in 53% of patients, including biliary obstruction, biliary tract infection, and sepsis.
• A fatal adverse reaction of hepatic failure occurred in one patient.
• The safety of Ziihera has not been established in patients with a baseline ejection fraction below 50%.
• Ziihera can cause infusion-related reactions, diarrhea, and left ventricular dysfunction.

Risks

• Continued approval for Ziihera is contingent upon the results of the confirmatory Phase 3 trial.
• The drug has a boxed warning for embryo-fetal toxicity, requiring effective contraception during treatment.
• There are risks of serious adverse reactions, including infusion-related reactions, diarrhea, and left ventricular dysfunction.
• The safety profile for Ziihera has been demonstrated in 80 patients in the HERIZON-BTC-01 trial, which is a relatively small sample size.
• The company is reliant on the success of ongoing clinical trials to expand the use of zanidatamab to other tumor types.

Future Outlook

Jazz Pharmaceuticals plans to continue research of zanidatamab in BTC and other HER2-expressing solid tumors, with the goal of improving outcomes for more people diagnosed with these difficult-to-treat HER2-positive cancers. The company is also conducting a Phase 3 confirmatory trial and investigating zanidatamab in other tumor types.

Management Comments

• Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals, stated that the approval of Ziihera is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC.
• Dr. James Harding, associate attending, Gastrointestinal Oncology and Early Drug Development Services, at Memorial Sloan Kettering Cancer Center, noted that zanidatamab has demonstrated antitumor activity and is now a new option for patients with HER2-positive biliary tract cancer.
• Stacie Lindsey, CEO and founder of the Cholangiocarcinoma Foundation, stated that the approval of Ziihera offers a promising treatment option and provides patients and their loved ones the possibility of more time together and an improved quality of life.

Industry Context

This announcement is significant as it addresses a high unmet need in the treatment of HER2-positive biliary tract cancer, a disease with limited treatment options and poor prognosis. The approval of Ziihera, a dual HER2-targeted bispecific antibody, represents a novel approach in this space and could potentially change the treatment paradigm for this patient population.

Comparison to Industry Standards

• The 52% objective response rate for Ziihera is notable compared to historical outcomes for patients with previously treated HER2-positive biliary tract cancer, where response rates to standard chemotherapy are typically much lower.
• While direct comparisons are challenging due to variations in trial design and patient populations, the 14.9-month median duration of response is also encouraging, as many existing treatments offer shorter durations of benefit.
• Other companies such as Roche and AstraZeneca have HER2-targeted therapies, but Ziihera is the first bispecific antibody approved for this specific indication, setting it apart from traditional monoclonal antibodies.
• The ongoing Phase 3 trial will provide further data to compare Ziihera to standard-of-care therapies in the first-line setting, which will be crucial for establishing its place in the treatment landscape.

Stakeholder Impact

• Shareholders will likely view the FDA approval positively, potentially leading to an increase in stock value.
• Patients with HER2-positive biliary tract cancer now have a new treatment option, which could improve their prognosis and quality of life.
• Healthcare providers will have a new tool to treat this challenging disease.
• Employees of Jazz Pharmaceuticals may experience increased job security and opportunities due to the success of this drug.
• The company's partners, such as BeiGene and Zymeworks, may also benefit from the approval.

Next Steps

• Jazz Pharmaceuticals will host an investor webcast on December 11, 2024, to discuss the clinical data, patient need, and commercialization strategy for Ziihera.
• The company will continue the Phase 3 HERIZON-BTC-302 confirmatory trial to evaluate zanidatamab in combination with standard-of-care therapy.
• Jazz Pharmaceuticals will continue to investigate zanidatamab in other tumor types, including gastroesophageal adenocarcinomas and metastatic breast cancer.

Key Dates

Keywords

Ziihera, zanidatamab, biliary tract cancer, HER2-positive, FDA approval, bispecific antibody, oncology, cancer treatment, HERIZON-BTC-01, HERIZON-BTC-302